Small molecule inhibitor of the JAK family of kinases

US12390451B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Edward F. Attiyeh · Villanova, US
• Kurtis E. Bachman · Chester Springs, US
• Gerald C. Chu · Philadelphia, US
• Tatiana Koudriakova · Poway, US
• David Polidori · Rancho Santa Fe, US
• Gary Borzillo · Old Lyme, US

Key dates

• Filing date: Mar 9, 2022
• Grant date: Aug 19, 2025
• Expiry date: Mar 9, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are JAK inhibitors that have low systemic toxicity. In some aspects, the disclosure includes methods for treating disease states, disorders, and conditions mediated by JAK, such as stomacho-intestinal system cancers, including colorectal cancers and familial adenomatous polyposis.